Clinical Research Directory
Browse clinical research sites, groups, and studies.
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
Sponsor: Centre Hospitalier Universitaire de Nice
Summary
This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cell therapy for refractory non-Hodgkin's lymphoma or in relapse.
Official title: Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma: Pilot Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2022-08-29
Completion Date
2025-12-10
Last Updated
2026-06-17
Healthy Volunteers
No
Interventions
blood samples and 18FDG PET-CT exams
* 18 FDG PET scanner at inclusion and post CART-cells treatment ( 1, 3, 6, 9 and 12 month) * blood collection at inclusion and post CART-cells treatment (7 days, 1 month and 3 month)
Locations (1)
CHU de Nice
Nice, France